Thermostable Vaccines Market Report Scope & Overview:

The Thermostable Vaccines Market was valued at USD 9.15 Billion in 2025 and is expected to reach USD 19.94 Billion by 2035, growing at a CAGR of 8.10% from 2026-2035

Thermostable vaccines remain active above the two-to-eight degrees Celsius range through processes such as lyophilization, stabilizing excipients, dried microarray patches, and re-engineering of adjuvants. Such improvements facilitate distribution of the vaccines in regions with poor electrical infrastructure and irregular refrigeration systems, reducing any loss due to temperature exposure. Manufacturers in China and Japan remain at the forefront of innovation, developing thermostable forms of existing vaccines, as well as other new recombinant and viral vector vaccines, on the back of public health investment. In Southeast Asia, including Indonesia, Vietnam, and the Philippines, there are government-sponsored vaccination initiatives that have increased the purchase of thermostable vaccines. Such vaccines allow for distribution to distant islands and rural areas.

⮞Gavi, the Vaccine Alliance, reported on June, 2025 that its Global Health Summit in Brussels secured more than USD 9 Billion in pledges toward its 2026-2030 strategic funding cycle.

U.S. Thermostable Vaccines Market Outlook:

The U.S. Thermostable Vaccines Market was valued at USD 2.92 Billion in 2025 and is expected to reach USD 6.08 Billion by 2035, growing at a CAGR of 7.60% from 2026-2035.

Demand is anchored by federal biodefense procurement through the Biomedical Advanced Research and Development Authority, which continues to fund clinical development of oral, thermostable, and needle-free vaccine platforms aimed at pandemic preparedness and biosecurity readiness. National biotechnology companies developing oral and recombinant vaccine candidates are advancing late-stage clinical programs supported by government contracts, while established vaccine manufacturers continue to reformulate existing cold-chain-dependent products to extend shelf-life specifications and reduce distribution costs across rural and underserved national markets. Academic medical centers and contract research organizations running thermostability and stability-testing studies are also expanding capacity to support the growing pipeline of candidates moving from preclinical research into human trials across the country.

⮞Micron Biomedical announced on October, 2026 a vaccine development agreement with the U.S. Centers for Disease Control and Prevention to advance a live-attenuated rotavirus vaccine delivered through the skin without needles.

By Vaccine Type, Inactivated and Subunit Vaccines Dominates the Thermostable Vaccines Market and mRNA and Viral Vector Vaccines Grows Fastest

Inactivated and subunit vaccines hold the leading share of the thermostable vaccines market in 2025, reflecting decades of established manufacturing know-how and a comparatively straightforward path to reformulating these platforms with thermostabilizing excipients and lyophilization techniques. National immunization programs across low- and middle-income countries continue to rely heavily on inactivated and subunit formulations for routine childhood vaccination schedules, and manufacturers serving these programs have prioritized thermostability upgrades for existing approved products rather than pursuing entirely new antigen platforms. Multilateral procurement agencies have also written updated thermostability specifications into recent tenders covering pentavalent and hepatitis vaccines, reinforcing continued investment in this established vaccine category.

mRNA and viral vector vaccines represent the fastest-growing vaccine type, as developers extend thermostabilization research first proven on traditional platforms into newer nucleic-acid-based formulations that have historically required ultra-cold storage. Academic researchers and specialty biotechnology companies are developing dried, lipid-nanoparticle-free mRNA formulations and needle-free delivery systems intended to stabilize these vaccines at refrigerator or ambient temperature, a capability that would meaningfully expand their usability in outbreak response settings. Coalition-backed research funding focused specifically on thermostable mRNA platforms is accelerating preclinical and early clinical progress across several development programs worldwide.

⮞Vaxxas Pty. Ltd. announced on January, 2025 that it is partnering with the Coalition for Epidemic Preparedness Innovations to develop thermostable mRNA vaccines delivered through its needle-free high-density microarray patch.

By Route of Administration, Injectable Dominates the Thermostable Vaccines Market and Needle-Free Grows Fastest

Injectable administration remains the dominant route for thermostable vaccines in 2025, consistent with its position as the established standard across nearly all licensed immunization programs worldwide. Health systems, cold-chain logistics providers, and clinical staff training programs are all built around injectable delivery, giving manufacturers a well-understood regulatory and commercial pathway when introducing thermostable reformulations of existing injectable products. Large-scale government procurement contracts for routine childhood and travel-health immunization continue to specify injectable formulations by default, reflecting both regulatory precedent and the depth of clinical familiarity built up over decades of injectable vaccine use.

Needle-free administration, delivered through oral formulations and dissolvable microarray patches, is the fastest-growing route as developers pursue delivery methods that pair naturally with thermostable formulations and reduce dependence on trained clinical staff for administration. Needle-free platforms are particularly well suited to outbreak response and remote immunization campaigns, where minimizing sharps waste, administration training requirements, and cold-chain infrastructure simultaneously improves both safety and reach. Clinical trial data published in peer-reviewed journals demonstrating comparable immune response to licensed injectable vaccines is building regulatory and clinical confidence in these emerging delivery formats.

By Disease Indication, Infectious Diseases Dominates the Thermostable Vaccines Market and Pandemic Preparedness and Emerging Infectious Diseases Grows Fastest

Infectious diseases represent the largest disease indication for thermostable vaccines in 2025, covering established immunization targets such as tetanus, diphtheria, pertussis, hepatitis, and poliomyelitis that form the backbone of routine national vaccination schedules. Multilateral immunization programs continue to prioritize thermostability upgrades for these high-volume, well-established vaccines because even incremental formulation improvements translate into substantial reductions in wastage across the large volumes procured annually. Manufacturers supplying these programs have correspondingly directed much of their thermostabilization research toward formulations already embedded in global immunization schedules rather than toward entirely new indications.

Pandemic preparedness and emerging infectious disease indications are growing fastest, reflecting heightened global investment in rapid-response vaccine platforms capable of being manufactured, distributed, and administered without reliance on cold-chain infrastructure during an active outbreak. Government biodefense agencies and multilateral health funders have increased financial commitments toward thermostable platform technologies that can be rapidly adapted to new pathogens, recognizing that outbreak response speed is frequently constrained as much by distribution logistics as by vaccine development timelines themselves. This strategic emphasis is attracting dedicated funding rounds for specialty biotechnology companies focused on rapid-response formulation science.

⮞Soligenix said in May 2026 that its thermostable vaccine platform could support rapid development of a vaccine against Bundibugyo virus, the strain driving the ongoing Ebola outbreak in the Democratic Republic of the Congo and Uganda.

By Distribution Channel, Government and Institutional Procurement Dominates the Thermostable Vaccines Market and Private and Retail Pharmacy Grows Fastest

Government and institutional procurement remains the dominant distribution channel for thermostable vaccines in 2025, reflecting the central role that national immunization programs and multilateral agencies such as Gavi and UNICEF play in financing and distributing vaccines across low- and middle-income countries. Large multi-year procurement agreements negotiated directly with manufacturers give these institutional buyers meaningful influence over product specifications, including thermostability requirements written into tender documentation, which in turn shapes manufacturer reformulation priorities across the broader market. Long-term supply agreements of this kind give institutional buyers substantial pricing leverage, and manufacturers serving these contracts routinely dedicate a meaningful share of annual production capacity to fulfilling multi-year commitments ahead of newer or smaller customer accounts.

Private and retail pharmacy distribution is the fastest-growing channel, driven by rising consumer demand for travel-health and seasonal vaccines administered through community pharmacy networks in developed markets. Pharmacy chains in North America and parts of Europe have expanded their immunization service offerings in recent years, and thermostable formulations that do not require dedicated pharmaceutical refrigeration simplify inventory management for these retail locations. Manufacturers are correspondingly developing packaging and distribution partnerships tailored specifically to retail pharmacy logistics requirements rather than the bulk institutional shipment formats used for government procurement.

Regional Analysis:

North America Thermostable Vaccines Market Insights

With a share of 38.00% in 2025, North America led the market, supported by sustained federal biodefense procurement and a concentration of specialty biotechnology companies advancing oral, recombinant, and needle-free vaccine candidates through late-stage clinical trials. The Biomedical Advanced Research and Development Authority continues to fund thermostabilization research across multiple vaccine platforms as part of broader pandemic preparedness planning, giving national developers a reliable funding channel not consistently available to peers in other regions. Canada contributes a smaller but stable share of regional demand, driven primarily by federal procurement of travel-health and routine immunization products from established multinational manufacturers.

Clinical-stage companies in the United States developing oral norovirus and other mucosal vaccine candidates are advancing through Phase 2 and Phase 3 trials with government co-funding support, reflecting sustained policy emphasis on reducing cold-chain dependency across the national vaccine stockpile. Contract research organizations and academic medical centers running stability and thermostability testing studies have expanded capacity to support this growing pipeline, and several national manufacturers are simultaneously reformulating already-licensed products to extend shelf-life specifications for both national distribution and export to allied immunization programs serving partner countries across multiple continents.

⮞Bavarian Nordic announced on March, 2025 that the U.S. FDA approved a freeze-dried formulation of its JYNNEOS smallpox and mpox vaccine, which is easier to store and transport than the liquid-frozen version and better suited to government stockpiling.

Asia Pacific Thermostable Vaccines Market Insights

Asia Pacific is the second-largest regional market by share but the fastest-growing region overall, with a CAGR of 9.80% from 2026-2035, supported by India's position as one of the world's largest vaccine manufacturing bases and by growing government investment in national immunization infrastructure across South and Southeast Asia. Indian manufacturers supplying pentavalent, oral, and other thermostable vaccine formulations to international immunization programs have continued to scale production capacity, supported by export demand from multilateral procurement agencies serving low-resource markets across Africa and South Asia.

China and Japan are still innovation hotspots for vaccine platform development, with a number of national manufacturers pursuing thermostable reformulations of existing products as well as newer recombinant and viral vector candidates, supported by increasing state-level public health investment across the region. Thermostable formulations that do not require consistent cold-chain infrastructure are seeing incremental procurement volumes across Southeast Asian markets including Indonesia, Vietnam and the Philippines, driven by government-backed immunization expansion programs. This logistical constraint has historically limited full immunization coverage across the region as it enables delivery to remote island and rural populations.

⮞Serum Institute of India, the world's largest vaccine manufacturer by volume, continued expanding production capacity at its Pune facilities through 2025 and 2026 to meet rising global demand.

Europe Thermostable Vaccines Market Insights

Europe is the third-largest regional market, with an estimated 22.00% share in 2025, anchored by a concentration of specialty biotechnology companies and academic research networks developing fridge-free vaccine reformulations in partnership with national health services. United Kingdom-based developers have published peer-reviewed clinical trial data demonstrating comparable immunogenicity between thermostable reformulations and licensed cold-chain-dependent equivalents, building regulatory and clinical confidence that is expected to support continued investment across the region's vaccine development sector. Public research funding bodies in the United Kingdom have also co-financed several of these academic-industry collaborations, reflecting sustained national policy interest in reducing cold-chain dependency across routine immunization programs.

Regulatory frameworks administered by the European Medicines Agency are generally regarded by multinational vaccine developers as a rigorous benchmark, encouraging companies to pursue European regulatory review for expanded or reformulated vaccine indications before extending filings to other jurisdictions. National health services across Germany, France, and the Nordic countries continue to update seasonal and routine immunization procurement specifications, incorporating thermostability considerations as part of broader efforts to reduce distribution costs and improve rural and remote-area immunization coverage across the region, with several agencies also piloting needle-free delivery formats within smaller regional vaccination campaigns.

⮞Ensilicated Technologies Ltd. (EnsiliTech), a University of Bath spin-out, raised GBP 4.5 Million in an oversubscribed seed round in August 2025 to advance its silica-based ensilication technology for keeping vaccines and biologics stable without refrigeration.

MEA & Latin America Thermostable Vaccines Market Insights

The Middle East and Africa is a smaller but growing market for thermostable vaccines, estimated to share 6.00% of the market in 2025, with growth focused in national immunization programs that aim to extend vaccination coverage to remote and rural communities without reliable refrigerated transport infrastructure. Gulf Cooperation Council governments have expanded their funding commitments for regional vaccine manufacturing and distribution infrastructure, while sub-Saharan African immunization programs remain reliant on multilateral procurement support from Gavi and UNICEF for access to thermostable formulations suitable to the region’s logistical constraints.

Latin America was a smaller 5.00% in 2025 with Brazil the largest country market in the region due to its established domestic vaccine manufacturing capabilities and broad-based public immunization program. Remote and riverine communities throughout the Amazon basin and other geographically isolated parts of the region continue to drive demand for thermostable formulations that reduce dependence on refrigerated transport across difficult terrain. Mexico and Colombia are also increasing national procurement budgets for immunizations to support incremental demand for thermostable vaccines, while continuing to invest in regional public health distribution infrastructure.

Market Dynamics:

Growth Drivers: Reducing vaccine wastage from cold-chain failures is sustaining steady adoption

Persistent vaccine wastage caused by temperature excursions during storage and transport remains a primary driver of demand for thermostable formulations, as national immunization programs and multilateral funders seek to maximize the clinical and financial return on every dose procured. The World Health Organization has long attributed a substantial share of global vaccine losses to cold-chain failures in low-resource settings, and thermostable reformulations directly address this inefficiency by extending the temperature range and duration over which vaccines retain clinical potency, reducing the administrative and financial burden of maintaining refrigerated distribution networks.

A second driver is sustained multilateral funding commitment toward pandemic preparedness and outbreak response capability, with institutions such as Gavi and the Coalition for Epidemic Preparedness Innovations directing significant resources toward thermostable platform research specifically because rapid-response vaccines deployed during an outbreak frequently cannot rely on established cold-chain infrastructure. Continued government biodefense procurement in developed markets is expected to sustain research funding for thermostable reformulations throughout the remainder of the forecast period, reinforcing demand across both routine and emergency immunization use cases.

⮞Vaxart announced on June, 2026 a BARDA contract modification that released additional funding for its Phase 2b oral pill COVID-19 vaccine trial, bringing total authorized funding for the study to USD 344.8 Million.

Restraints: Reformulation and clinical revalidation costs limit near-term adoption

Converting an existing cold-chain-dependent vaccine into a thermostable formulation typically requires substantial reformulation research, stability testing across extended temperature ranges, and in many cases new clinical trials to confirm comparable immunogenicity, imposing meaningful cost and timeline burdens on manufacturers. Smaller biotechnology companies with limited capital reserves are particularly constrained in pursuing thermostabilization programs independently, often requiring partnership funding or government grants to advance candidates through the required stability and clinical validation studies, which can extend development timelines by several years relative to conventional cold-chain-dependent formulation programs pursued by larger, better-capitalized competitors.

A second restraint is that regulatory pathways for thermostable reformulations of already-licensed vaccines are not uniformly standardized across jurisdictions, creating uncertainty for manufacturers planning simultaneous filings in multiple markets. Some national regulators require full clinical revalidation even for formulation changes that preserve the original antigen, extending development timelines and increasing costs relative to simpler line-extension approvals, a factor that has led several manufacturers to prioritize thermostabilization programs for products with the largest existing procurement volumes first, deferring reformulation work on smaller or regionally specific vaccine lines until later in the forecast period.

⮞Stablepharma said in August 2026 that it expects to complete clinical development of its fridge-free SPVX02 tetanus-diphtheria vaccine by 2027, after its first-in-human trial began in 2025.

Opportunities: Needle-free delivery platforms are widening the addressable market

Growing clinical validation of needle-free delivery platforms, including oral formulations and dissolvable microarray patches, represents a meaningful opportunity for thermostable vaccine developers to expand into outbreak-response and remote-immunization use cases that injectable cold-chain-dependent products cannot efficiently serve. Partnerships between large, established vaccine makers and niche delivery-platform players are speeding the transition from lab-stage thermostabilization research to clinically validated products. This broadens the addressable market beyond traditional institutional procurement channels and creates new commercial opportunities in travel-health, humanitarian response and retail pharmacy settings, which have been traditionally underserved by traditional cold chain-dependent vaccine products.

A second opportunity is for regional vaccine manufacturers in South Asia and other emerging markets to scale up their capacity to produce thermostable vaccines and directly supply multilateral procurement programs, capturing demand that has historically gone to a handful of global incumbents. Over the next few years, India and other emerging production hubs are expected to attract increased investment in biosimilar and vaccine manufacturing, resulting in a more diversified global supplier base and new partnership and licensing opportunities for companies that possess thermostabilization intellectual property but lack large-scale manufacturing capacity of their own.

⮞AFT Pharmaceuticals reported in January 2026 that it had signed an agreement with Stablepharma to apply the StablevaX thermostable technology to a range of injectable products, with AFT planning to sell them in its own markets and out-license the technology elsewhere.

Thermostable Vaccines Market Key Players:

• Vaxart, Inc.

• Stablepharma Ltd.

• Bharat Biotech International Limited

• Serum Institute of India Pvt. Ltd.

• Vaxxas Pty Ltd.

• Ensilicated Technologies Ltd. (EnsiliTech)

• Micron Biomedical, Inc.

• Soligenix, Inc.

• Immunoscript Life Science

• Arcturus Therapeutics Holdings Inc.

• VitriVax, Inc.

Thermostable Vaccines Market Report Scope: